ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
David E. Gerber, John Dorrance Minna · Cancer Cell · 2010
Cited by 220 works. doi:10.1016/j.ccr.2010.11.033 Open-access PDF
Authors
References
- Cancer Statistics, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Somatic mutations affect key pathways in lung adenocarcinoma
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- A small-cell lung cancer genome with complex signatures of tobacco exposure
- High-throughput oncogene mutation profiling in human cancer
- Characterizing the cancer genome in lung adenocarcinoma
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer